Invasive Ductal Carcinoma - Biopsy (USA)

44 year old lady asymptomatic screening. Here you can see the. Insight to the views showing no significant lesions. If we move to chemo, we detect it. An irregular, even speculative mass. In the left breast. Not clearly detected only in review. Sleep compared to conventional 2D on the terminal. You can see the superiority of terminal to detect this suspicious lesion. Ultrasound was absolutely normal. So it is mandatory to have the possibility of performing atomo guided biopsy. And that is what we did. This is the thermal approach showing the index edition and it's very simple, you only have to make a click. What the issue is? This is the these are the profile the prefire images. Showing no lesions because of the hematoma and anesthetic. And. A final tomo. After the biopsy showing. The hematoma and the clip inside the hematoma. The final result was an invasive ductal cancer luminal, a subtype. So in conclusion, the Tomo guided biopsy is necessary for lesions that are only detected on tomosynthesis.

11 Biopsy 2 Digital Breast Tomosynthesis and Contrast Enhanced Mammography Prof. Dr. Luis Pina Breast Imaging Department (Radiología mamaria) Clínica Universidad de Navarra, Pamplona / Spain SIEMENS 10_Biopsy_2, PID3640 Healthineers * 1/1/2022 F PID3640 Series Navigator INSIGHT_2D Add Study PID3640 5/1/2021 (Study date) Prior 02 TLOCSC CCST+ Viewing Favorite Layouts US MR DYN IN 2 C.US | C .... MR.Dyna ... N 2D IN 2D MR.Empty ReportFlow BASIC Printing Tools Findings MR 5:07 PM Clinical information 44-year-old female lady Asymptomatic RCC RMLO LMLO Slice 30 / 98 Slice 35 / 101 Slice 32 / 88 Slice 45 / 88 Slice thickness: 1:00 mm Slice thickness: 1.00 mm Slice thickness: 1:00 mm L_MG_T Slice 46 / 88 Slice 65 / 101 Slice thickness: 1.00 mm LCCST+ BASI LCCSC Prior 01 Slice 54 / 88 Pathology Invasive ductal carcinoma (IDC) Luminal A, 5 mm Conclusion DBT guided biopsy is necessary for lesions only detected on DBT. Siemens Healthcare GmbH, 2022 Sometimes IN2D images (= synthetic mammograms) are shown while verbally referring to the conventional mammograms. The products/features (mentioned herein) are not commercially available in all countries. Their future availability cannot be guaranteed. Results from case studies are not predictive of results in other cases. Results in other cases may vary. The statements by Siemens' customers described herein are based on results that were achieved in the customer's unique setting. Since there is no "typical" setting and many variables exist (e.g ., hospital size, samples mix, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results. Dr. Luis Pina is employed by an institution that receives financial support from Siemens Healthineers for collaborations. Heal